Anti-platelet individual treatment guided by CYP2C19 polymorphism
WU Long-mei
XU Wei
TIAN Xin-li
YI Gui-yan
LI Jun-xia
Abstract：Objective To investigate the influence of anti-platelet individual treatment guided by CYP2C19 polymorphism on prognosis in patients with coronary heart disease (CHD) after stent implantation.Methods The patients (n=338) hospitalized and accepted success PCI due to acute coronary syndrome (ACS) were chosen from Nov. 2013 to May 2014, and finally 301 eligible patients were brought into the study. All patients were randomly divided into routine group and individual group, and routine group was treated with aspirin+clopidogrel for anti-platelet treatment. The individual group was divided again into LOF+ group and LOF- group according to CYP2C19 polymorphism, and LOF+ group was treated with aspirin+ticagrelor and LOF- group was treated with aspirin+clopidogrel. The incidence rates of major bleeding events and cardiovascular ischemia events were followed up within 9 m to 12 m.Results There was no statistical difference in sex, age, hypertension, diabetes, hyperlipidemia, smoking, multi-vessel lesion, number of stents and auxiliary examinations (total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, fasting plasma glucose, creatinine and uric acid) between 2 groups (allP>0.05). There was no statistical difference in safe endpoint (major bleeding events) and curative effect endpoint (major adverse cardiovascular events, in-stent thrombosis and reoccurrence angina pectoris) between 2 groups (allP>0.05).Conclusion The anti-platelet individual treatment guided by CYP2C19 polymorphism cannot reduce the incidence of cardiovascular endpoint events.
Keywords：CYP2C19ClopidogrelTicagrelorAnti-platelet individual treatment
Publication Date：2015-01-01
Pages：4( 207-210 )